Candidate Sequence Variants and Fetal Hemoglobin in Children with Sickle Cell Disease Treated with Hydroxyurea
Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, Neville KA, Hoppe C, Barral S. Candidate Sequence Variants and Fetal Hemoglobin in Children with Sickle Cell Disease Treated with Hydroxyurea. PLOS ONE 2013, 8: e55709. PMID: 23409025, PMCID: PMC3567082, DOI: 10.1371/journal.pone.0055709.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAllelesAnemia, Sickle CellAntisickling AgentsChildFemaleFetal HemoglobinGenotypeHumansHydroxyureaMalePolymorphism, Single NucleotideProspective StudiesConceptsSickle cell diseaseFetal hemoglobin levelsHemoglobin levelsCell diseaseFetal hemoglobinBaseline levelsAdult sickle cell diseasePediatric sickle cell diseaseSubset of childrenPharmacologic therapyHydroxyurea therapyClinical severityPediatric diseasesInduced levelsSignificant associationTherapeutic inductionCandidate single nucleotide polymorphismsDiseaseSingle nucleotide polymorphismsHemoglobinSequence variantsChildrenTherapyBaselineHydroxyurea